lenzilumab
mAbexperimentalCOVID-19
Lenzilumab is a humanized monoclonal antibody that targets colony stimulating factor 2 (CSF2)/granulocyte-macrophage colony stimulating factor (GM-CSF). — Wikipedia
Clinical trial activity
6 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
5
Phase 3
2
Phase 4
0
Earliest trial started Jan 1, 2010 (NCT00995449)
Timeline
Indications
Mechanism of action
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaLenzilumab ↗
- ChEMBLCHEMBL3707325 ↗
- ChEMBLCHEMBL2109431 ↗
Also known as
- enzilumab
- kb003
- kb-003
- lenzilumab
- lenzilumab
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04534725 | Phase 3 | Dec 17, 2020 | Peter MacCallum Cancer Centre |
| NCT04583969 | Phase 2 | Oct 19, 2020 | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT04351152 | Phase 3 | May 31, 2020 | Humanigen |
| NCT04314843 | Phase 1/Phase 2 (Phase 2) | Apr 30, 2020 | Gilead Sciences, Humanigen |
| NCT02546284 | Phase 1 | Jul 1, 2016 | Humanigen |
| NCT00995449 | Phase 2 | Jan 1, 2010 | Humanigen |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Humanigen | For profit | 4 | 3 | 3 | 2010 |
| Gilead Sciences | For profit | 1 | 1 | 1 | 2020 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 1 | 1 | 1 | 2020 |
| Peter MacCallum Cancer Centre | Academic/Hospital | 1 | 1 | 1 | 2020 |
4 organizations
Page 1 / 1